Reply to 'Rituximab activity in CD20-positive multiple myeloma'. | Leukemia;22(5): 1083; author reply 1083-4, 2008 May. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Reply to 'Rituximab activity in CD20-positive multiple myeloma'.

Gozzetti, A; Fabbri, A; Lazzi, S; Bocchia, M; Lauria, F.

Leukemia ; 22(5): 1083; author reply 1083-4, 2008 May.

Article in En | MEDLINE | ID: mdl-17972948

Subject(s)

Antibodies, Monoclonal/therapeutic use; Multiple Myeloma/drug therapy; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Humans; Remission Induction; Rituximab

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal / Multiple Myeloma Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Country of publication: United kingdom

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal / Multiple Myeloma Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Country of publication: United kingdom